ShareValue scores for ECR.MC: Valuation 68, Quality 16, Growth 40, Health 54.

ECR.MC
BME

Ercros

€3.49(+0.14%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 18%
Valuation
68
Fair Value
Price vs Value
Quality
16
Weak
Business Strength
Growth
40
Weak
Revenue & Earnings
Health
54
Moderate
Financial Stability
Momentum
71
Bullish
Price Trend

Company Details

About

Ercros, S.A., together with its subsidiaries, manufactures and sells chemical and pharmaceutical products in Spain and internationally. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmaceuticals. The company offers ammonia, caustic soda and potash, chlorine chloroisocyanurates, dichloroethane, ercrosbio, hydrochloric acid, hydrogen peroxide, polyvinyl chloride, potassium carbonate, PVC compounds, sodium chlorate, sodium chlorite, sodium hypochlorite, sulfuric acid, and vinyl chloride. It also provides dipentaerythritol, ercrosgreen + resins, formaldehyde, methanol, moulding compounds, paraformaldehyde, pentaerythritol, and sodium formate. In addition, the company offers generic active pharmaceutical ingredients, including amlodipine besylate, azithromycin, clarithromycin, erythromycin, famotidine, fosfomycin, and fusidic acid, as well as customized production of antibiotics, anti-hypertensives, and anti-ulcer drugs. It exports its products. The company was formerly known as S.A. Cros and changed its name to Ercros, S.A. in June 1989. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026